- ABOUT US
With FDA approval and EU certification, Celltrion Pharm’s products are now expanding to the global markets.
Celltrion Pharm brings possibilities to reality. We develop distinguished products by putting our best efforts and continuous researches.
Celltrion Pharm will keep on developing for those who need our expertise and products.
Celltrion Pharm promises hope. We will create medicines that elevate the value of life.
Here are the latest news about Celltrion Pharm.
Notice to shareholders regarding: The conclusion of government financial audit and the Securities & Futures Commission’s review
■ During the last 57 months, since Jun 2017, we have sincerely participated in the audit conducted by the financial authorities on its financial statements for 12 fiscal years. We have faithfully explained our position on the issues raised during this audit. As the decisions announced by Securities & Futures Commission (SFC) on Mar 11, 2022, officially mark the finalization of this audit, we believe that these decisions eliminate a significant portion of the uncertainty about Celltrion Pharms that has existed in the financial market for a long time. These decisions also clear up some of the misunderstandings caused by the differences in opinion between the financial authorities and Celltrion Pharms. ■ It is unfortunate that SFC has found some of our accounting practices in violation of the accounting standards. While we believe that these findings were caused by the different views on how the unique nature of biopharmaceuticals and the relevant international rules are incorporated into our accounting exercises, we respectfully accept SFC’s decisions. ■ The accounting practices that were viewed as violations of the accounting standards occurred in the past, hence having no impact on our current financial statements. ■ With the audit inspection finally resolved, we and the affiliates of Celltrion Group will remain committed to our key business to meet the market and shareholder expectations.2022-03-11 08:42
Notice to shareholders
Regarding the recent news article about the Financial Services Commission’s audit inspection, Celltrion Group would like to state the following: ■ Celltrion Group learned that a daily newspaper had published an article about some matters pertaining to the progress of the ongoing audit inspection by the financial regulators. ■ Some information contained in the article does not fully reflect the truth. As the audit inspection is still ongoing, no conclusion has been drawn at this stage. ■ Celltrion Group has sincerely explained its position so far and will continue to do so in full compliance with the audit inspection process.2022-01-17 07:29
[Message to Investors] Celltrion Group’s Statement on the development of a therapeutic antibody treatment to combat COVID-19
■ Celltrion Group was among the first that have embarked on the development of a therapeutic antibody treatment and a diagnostic kit on the onset of the global spread of the novel coronavirus, in a bid to contribute to stopping what would escalate into the coronavirus pandemic. ■ As Celltrion Group Chairman Seo Jung-jin has said earlier, the development of these solutions is driven by our commitment to placing the public interest before our own. Simply put, we are acting on our responsibility as a faithful member of the global pharmaceutical community as we willingly step forward to help address the global coronavirus pandemic. ■ Our researchers are working round the clock to contribute to the world’s common battle to defeat the COVID-19 pandemic. We ensure that any significant progress is promptly, and transparently, shared with the world, because we would like to give the people a sense of hope that we are moving towards an end of these difficult times. ■ We advise our investors to understand that our efforts to develop a coronavirus treatment and a diagnostic kit are not commercially motivated, and their investment decisions should be made based on our business records and the underlying value of our product portfolio. ■ Leading the global antibody biosimilar market, we have been growing continuously on the back of our robust fundamentals. With the successful development and global launches of monoclonal antibody biopharmaceuticals such as Remsima, Truxima, Herzuma, and Remsima SC, Celltrion is becoming a global pharmaceutical corporation representing South Korea. ■ We ask for your continued interest in our vision for future growth as we continue to build upon our own technological capabilities and R&D know-how.2020-04-13 04:51
Celltrion Pharm runs businesses that elevate the value of life.
With production facilities and technologies on par with global standards, we supply safe and high-quality chemical products to the marketVIEW MORE
We provide patients with opportunities to use high-quality biopharmaceutical products at reasonable prices.VIEW MORE
From pharmaceutical development to finished product manufacture, we offer customized contract manufacturing services using our global-standard pharmaceutical production facilities.VIEW MORE
Celltrion Pharm offers better opportunities and environments for treatment.
Godex Cap. is a hepatoprotective agent mainly consisting of carnitine that helps in mitochondria’s structure and functions. It was developed with the mixture that helps Hepadif and DDB achieve their effects. In particular, Godex Cap. is used for hepatic diseases related to elevated transaminase values.
Treble Tab is a triple combination medicine that combines ARB telmisartan, CCB amlodipine, and RosuvastatinStatin, a hyperlipidemia medicine. It is used for hypertension patients with hyperlipidemia.
Remsima is a biosimilar of Infliximab, approved by the European Medicines Agency (EMA) in 2013 and the United States Foods and Drug Administration (FDA) in April 2016. It is used for the treatment of rheumarthritis, spondylitis ankylopoietica, ulcerative colitis ulcerativa, Crohn disease in adults and children, and psoriasis.
Herzuma® a biosimilar of Trastuzumab, approved by the European Medicines Agency (EMA) in February 2018 and the United States Foods and Drug Administration (FDA) in December 2018. It is used for the treatment of metastatic breast cancer with HER2 overexpression, early breast cancer, and metastatic gastric cancer.
Truxima® is a biosimilar of Rituximab, approved by the European Medicines Agency (EMA) in February 2017 and the United States Foods and Drug Administration (FDA) in 2018. It is used for the treatment of lymphoma, chronic lymphocytic leukemia, and rheumarthritis.